BB100

BB100 LLC is a biotechnology company and a subsidiary of Bravos Biosciences focused on the development of novel monoclonal antibody therapies for multi-drug resistant (MDR) infections. The company's lead program, BB100 (formerly ASN-4), is a humanized monoclonal antibody licensed from Arsanis that targets the lipopolysaccharide (LPS) O25b antigen of hyper-virulent Escherichia coli strains, such as the ST131-O25b:H4 clone. BB100 is designed to be directly bactericidal and provide anti-inflammatory effects, offering a potential non-antibiotic alternative for treating complicated urinary tract, bloodstream, and prostate infections. The company has received significant non-dilutive funding from CARB-X to advance the program through clinical development. BB100 LLC is led by a team of experts in anti-infective translational science and pharmacokinetic-pharmacodynamic (PK-PD) principles. The company operates out of Schenectady, New York, and leverages advanced modeling to optimize drug development for difficult-to-treat pathogens.